2023年7月17日

WGN電台的采訪。但最近FDA批準為醫療保險和其他保險公司鋪平了道路的藥物。Chiquita Brooks-LaSure醫療管理員表示,該計劃將開始支付藥物現在已經完全FDA批準。但是政府也設置額外的要求,包括登記在聯邦注冊跟蹤藥物的真實世界的安全性和有效性。“我看,說這是我們的機會證明藥物是正常工作。它將推動其他5、6、7的藥物現在的管道,在做類似的事情取消β澱粉樣蛋白在大腦,“大多數博士說。甚至忽視成本或保險,並不是每一個人與阿爾茨海默氏症能夠染指的藥物。醫生需要確認病人的大腦斑塊Leqembi處方前的目標。“當你看看650萬老年癡呆症患者,它會下降1到200萬之間的分類可能個人將提供或將被允許,“大多數博士說。“因為我們看那些阿爾茨海默氏症的早期階段,輕微症狀,是否我們可以阻止它。” Leqembi's drugmaker Eisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026. Eisai studied the drug in people with early or mild disease who were evaluated using a scale measuring memory, thinking and other basic skills. After 18 months, those who got Leqembi declined more slowly — a difference of less than half a point on the scale — than participants who received a dummy infusion. Some Alzheimer's experts say that delay is likely too subtle for patients or their families to notice. Hear more from